Human Papillomavirus in Young People Epidemiological Research 3

A Cross-sectional Study to Evaluate the Prevalence of HPV in Gay and Bisexual Men Aged 16-20 Years in Australia

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05587725

Acronym

HYPER3

Enrollment

200

Registered

2022-10-20

Start date

2023-01-01

Completion date

2025-12-31

Last updated

2023-03-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anal Cancer, Cancer, HPV, HPV 16 Infection, HPV Infection, Human Papillomavirus Infection, Men

Keywords

Vaccination, Vaccine, Public health, Prevention, Men who have sex with men, Gay and bisexual men, Immunisation

Brief summary

Anal cancer is overrepresented among gay, bisexual and other men who have sex with men (MSM), particularly those living with HIV. Australia was the first country to introduce a publicly funded national HPV vaccination program in 2007. This program was expanded to include schoolboys aged 12-13 years in 2013; with a 2-year catch-up for boys aged up to 15 years. In 2018, the 9-valent vaccine (covering genotypes 6/11/16/18/31/33/45/52/58) replaced the 4-valent vaccine in the national program. The goal of the HYPER3 study is to determine the prevalence of anal, genital and oral HPV among 200 young gay and bisexual men aged 16-20 years who were eligible for the school-based 9-valent vaccination. Participants will be required to complete a questionnaire and provide samples for HPV testing. No follow-up visits will be required.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

MALE

Age

16 Years to 20 Years

Healthy volunteers

Yes

Inclusion criteria

* Men aged 16 to 20 (i.e. men aged 16-18 years in 2023; men aged 16-19 years in 2024; and men aged 16-20 years in 2025 will be recruited. This is to ensure these men would have been eligible for the 9-valent school-based HPV program) * Same-sex attracted * Residing in Australia since 2018

Exclusion criteria

* Unable to complete all study requirements in English

Design outcomes

Primary

Measure	Time frame	Description
Prevalence of quadrivalent vaccine HPV types	Baseline	The oral, penile and anal prevalence of quadrivalent vaccine types (6, 11, 16 and 18)
Prevalence of nonavalent vaccine HPV types	Baseline	The oral, penile and anal prevalence of nonavalent vaccine types (6, 11, 16, 18, 31,33, 45, 52 and 58)
Prevalence of type-specific HPV types	Baseline	The oral, penile and anal prevalence of type-specific HPV types

Countries

Australia

Contacts

Primary ContactEric Chow, PhD

eric.chow@monash.edu+61393416233

Outcome results